Ilidotrans Transdermal Patch contains Lidocaine 700 mg, a potent local anesthetic indicated for the management of localized pain associated with conditions such as postherpetic neuralgia, peripheral neuropathy, and musculoskeletal disorders. The patch delivers a controlled and sustained release of lidocaine through the skin, providing effective analgesia by stabilizing neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses. This transdermal system offers targeted pain relief with minimal systemic absorption, thereby reducing the risk of systemic side effects commonly associated with oral analgesics. Ilidotrans is designed for ease of application, adhering securely to the affected area and allowing for continuous drug delivery over an extended period, typically up to 12 hours per patch. It is recommended to apply the patch to intact, non-irritated skin and to avoid use on open wounds or mucous membranes. Patients should be advised to monitor for potential local reactions such as erythema, edema, or pruritus at the application site. Ilidotrans Transdermal Patch should be used under medical supervision, especially in patients with known hypersensitivity to amide-type anesthetics or those with severe hepatic impairment.